Aqueduct Medical

Company Overview

Snapshot

Founded in July 2013 by Omer Harpaz, Aqueduct Medical operates with 1–10 employees. The company has raised $1.3 million across one funding round from three investors, including NGT3. In September 2016, the company received FDA approval for its cervical dilator device.

Business overview

Aqueduct Medical develops medical devices for dilating the uterine cervix and other organs, aiming to reduce discomfort and complications during intrauterine procedures. Its core technology combines the benefits of rod dilation and laminaria, enabling rapid radial dilation with a single insertion. The company's solutions are designed for hospitals and clinics, serving healthcare providers and patients in the gynecology and women's health sectors, particularly in the United States.

Strategic signal

In September 2016, Aqueduct Medical secured FDA approval for its cervical dilator device. This regulatory milestone validated the device's safety and efficacy, positioning the company to advance its product into clinical use and address a critical need in women's health.

Company Intelligence Q&A

What is Aqueduct Medical's primary focus?

Aqueduct Medical focuses on developing technology for dilating the uterine cervix and other organs, aiming to alleviate discomfort and potential complications during intrauterine procedures.

When was Aqueduct Medical founded?

Aqueduct Medical was founded in July 2013.

What was a significant regulatory milestone for Aqueduct Medical?

In September 2016, Aqueduct Medical received FDA approval for its cervical dilator device.

How much capital has Aqueduct Medical raised?

Aqueduct Medical has raised $1.3 million in total funding.

Which investors participated in Aqueduct Medical's funding round?

Aqueduct Medical received $1.3 million in funding from Israel Innovation Authority and NGT3 in a Seed round.